Access cutting-edge endometrial cancer treatment through this clinical trial at a research site in Duarte. Study-provided care at no cost to qualified participants.
Access endometrial cancer specialists in Duarte at no cost
This study follows strict safety protocols and ethical guidelines
All study-related endometrial cancer treatment provided free
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.
Sponsor: AstraZeneca
Check if you qualify for this endometrial cancer clinical trial in Duarte, CA
If you're searching for endometrial cancer treatment options in Duarte, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Duarte research site is actively enrolling participants for this clinical trial. You'll receive care from experienced endometrial cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.